2022 Will Be A Test For Gilead, Starting with TROPiCS-2 Study Of Trodelvy

Gilead Highlights Oncology Ambitions In Q4

 
• By Alaric DeArment

Even as magrolimab stumbled, the company remains optimistic about the rest of its pipeline, from potential pipeline-in-a-pill Trodelvy to an oral COVID-19 drug.

Overcoming challenges and crisis . Mixed media
Gilead touted its oncology pipeline in its fourth quarter/full year 2021 earnings • Source: Shutterstock

More from Earnings

More from Business